Скачать или смотреть FDA Gave Precigen (PGEN) a Monopoly in This Market and Competitors Are Running Out of Time

FDA Gave Precigen (PGEN) a Monopoly in This Market and Competitors Are Running Out of Time

In this video, I break down Precigen (PGEN) and its first-mover advantage following the FDA approval and commercial launch of PAPZIMEOS for adults with RRP. I analyze competitive threats from INOVIO (INO), early adoption data, payer coverage, and why Precigen’s launch execution is unusually strong for a rare-disease biotech. Finally, I look at the financial runway, path to cash-flow break-even, and why PGEN stands out as a high-potential stock under $5 for investors watching upcoming catalysts.

I use Interactive Brokers to buy most of the stocks I talk about. Create an account and get FREE stocks here: https://ibkr.com/referral/olivier574

Disclaimer
This video is for educational and entertainment purposes only and is not investment advice. I am purely documenting my opinions on companies that interest me. I am not a Financial Advisor and I am not your Financial Advisor. You risk losing your money by investing. Please do your own due diligence and get advice from an expert. I am human and get things wrong.

Tags
PGEN, Precigen, PGEN stock, Precigen stock, PGEN stock analysis, biotech stocks, biotech stock analysis, small cap biotech stocks, undervalued biotech stocks, high growth biotech stocks, biotech stocks to watch, healthcare stocks, pharmaceutical stocks, growth stocks, long term investing, stock market investing, FDA approval stocks, catalyst driven stocks, speculative biotech stocks, emerging biotech stocks, rare disease biotech, gene therapy stocks, best stocks under $5, stocks under $5, cheap stocks to buy, penny stocks, penny stocks to buy, high potential penny stocks, undervalued stocks under $5, Inovio, INO, Inovio Stock, INO stock